Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters
Fri, 06/7/24 - 11:32 am
Tags:
AbbVie, Humira, biosimilars
After AbbVie's ImmunoGen buy, Elahere posts midstage trial win in ovarian cancer subtype
Fierce Pharma
Thu, 06/6/24 - 09:13 pm
Tags:
AbbVie, antibody-drug conjugates, Elahere, Immunogen
AbbVie treats first subject in Phase III multiple myeloma drug trial
Clinical Trials Arena
Thu, 06/6/24 - 11:31 am
Tags:
AbbVie, clinical trials, ABBV-383, Multiple Myeloma
Top ten biopharma R&D deals of 2024
Nature
Wed, 06/5/24 - 11:24 am
Tags:
R&D, Novartis, Argo Biopharmaceutical, Roche, MOMA Therapeutics, Boehringer Ingelheim, Suzhou Ribo Life Science, Eli Lilly, Isomorphic Labs, Merus, Gilead Sciences, Novo Nordisk, Neomorph, AbbVie, Umoja Biopharma, Merck KGaA, Caris Life Sciences, Voyager Therapeutics
ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena
Mon, 06/3/24 - 12:06 pm
Tags:
ASCO 2024, AbbVie, antibody-drug conjugates, Teliso-V, ABBV-400, ABBV-706, solid tumors
Big Pharma’s most improved drugs: a new generation of blockbusters
Pharma Voice
Tue, 05/14/24 - 11:34 am
Tags:
Big Pharma, Eli Lilly, Mounjaro, Novo Nordisk, Wegovy, JNJ, Tecvayli, Merck, Vaxneuvance, AbbVie, Qulipta, AstraZeneca, Saphnelo, Novartis, Leqvio, Roche, Genentech, Vabysmo, Amgen, Evenity, Pfizer, Vyndaqel
AbbVie joins psychedelic push, inks $2B+ next-gen neuro deal with Gilgamesh
Fierce Biotech
Mon, 05/13/24 - 10:21 pm
Tags:
AbbVie, psychedelics, Gilgamesh Pharmaceuticals, R&D
The 25 Most Popular Drugs by U.S. Spending
AARP
Fri, 05/10/24 - 11:33 am
Tags:
prescription spending, Ozempic, Rybelsus, Wegovy, Eliquis, Humira, Novo Nordisk, AbbVie
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters
Wed, 05/8/24 - 10:58 pm
Tags:
Teva Pharmaceutical, earnings, biosimilars, AbbVie, Humira
Sandoz delivers 6% sales growth with Humira biosimilar leading the charge
Fierce Pharma
Tue, 05/7/24 - 06:30 pm
Tags:
Sandoz, earnings, biosimilars, AbbVie, Humira
AbbVie Invests €150 million in New German Development Facility
European Pharmaceutical Manufacturer
Mon, 05/6/24 - 05:57 pm
Tags:
AbbVie, Germany, R&D, drug development
FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
BioSpace
Thu, 05/2/24 - 11:37 am
Tags:
Boehringer Ingelheim, Cyltezo, AbbVie, Huira, FDA, biosimilars
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes
Thu, 05/2/24 - 11:34 am
Tags:
CVS Caremark, AbbVie, Humira, biosimilars, Hyrimoz, Sandoz, PBMs
As Imbruvica bows out, AstraZeneca clinches early Calquence win in newly diagnosed MCL
Fierce Pharma
Thu, 05/2/24 - 11:31 am
Tags:
AbbVie, JNJ, Imbruvica, AstraZeneca, Calquence, mantle cell lymphoma
Trials to watch: Four ALS drugs to keep an eye on
Clinical Trials Arena
Tue, 04/30/24 - 06:34 pm
Tags:
ALS, clinical trials, Calico Life Sciences, AbbVie, ABBV-CLS-7262, AL-S Pharma, AP-101, Rapa Therapeutics, RAPA-501, Clene, CNMAu-8
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters
Sun, 04/28/24 - 11:18 pm
Tags:
AbbVie, Humira, PBMs, biosimilars
AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again
Fierce Pharma
Fri, 04/26/24 - 11:18 am
Tags:
AbbVie, Rinvoq, Regeneron, Sanofi, Dupixent, atopic dermatitis
AbbVie lifts profit forecast after Skyrizi sales beat expectations
Reuters
Fri, 04/26/24 - 11:12 am
Tags:
AbbVie, earnings
Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost
BioSpace
Fri, 04/26/24 - 11:09 am
Tags:
Cigna, Evernorth Health, Accredo, AbbVie, Humira, biosimilars
Emergence of ADCs as the “hot, new technology”
Pharmaphorum
Thu, 04/25/24 - 11:39 am
Tags:
antibody-drug conjugate, Immunogen, AbbVie, Seagen, Pfizer, cancer, M&A

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.